Clarity Pharmaceuticals Partners with Nucleus RadioPharma for Advanced Manufacturing Agreement
On April 14, 2026, Clarity Pharmaceuticals (ASX: CU6), a forward-thinking clinical-stage radiopharmaceutical company, announced the establishment of a Commercial Manufacturing Agreement with Nucleus RadioPharma. This strategic partnership aims at advancing the manufacturing of 64Cu-SAR-bisPSMA, a next-generation diagnostic tool specifically designed for improved cancer detection.
Nucleus RadioPharma is recognized as an innovative contract development and manufacturing organization (CDMO) in the radiopharmaceutical field. Their state-of-the-art facility in Rochester, Minnesota, has the capacity to produce about 50,000 patient doses annually. Additionally, they are set to open a new facility in Spring House, Pennsylvania, in 2028, which is expected to increase production capacity to 600,000 doses of 64Cu-SAR-bisPSMA per year. This ambitious expansion will significantly bolster Clarity's ability to serve major commercial markets across the United States and select international locations in Europe.
This agreement builds on an existing partnership established with Nucleus RadioPharma, which includes a Master Services Agreement and a Clinical Supply Agreement for 67Cu-SAR-bisPSMA since November 2024. The signing of this latest agreement signifies a critical phase in Clarity's ongoing efforts to scale its manufacturing capabilities as it approaches the anticipated commercial launch of 64Cu-SAR-bisPSMA. This product's success will depend on the outcomes of Phase III registrational trials, namely AMPLIFY and CLARIFY, followed by approval from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA).
Dr. Geoffrey Johnson, Chief Scientific Officer at Nucleus RadioPharma, expressed enthusiasm over the production of 64Cu-SAR-bisPSMA, highlighting its potential in identifying small prostate cancer lesions that current standard imaging tests often overlook. Improved visualization could lead to earlier detection and subsequent better patient management, underlining the importance of effective diagnostic imaging in extending life and improving outcomes.
Stephen Hahn, CEO of Nucleus RadioPharma, also voiced his excitement about the partnership, emphasizing their shared goal with Clarity of enhancing treatment options for cancer patients. As the market launch of 64Cu-SAR-bisPSMA approaches, the recently released data providing insight into its efficacy compared to existing PSMA PET imaging adds to the anticipation surrounding this product.
Clarity’s Executive Chairperson, Dr. Alan Taylor, reiterated the significance of this manufacturing strategy, stating that establishing a robust supply system for 64Cu-SAR-bisPSMA will facilitate a large-scale commercial launch from day one. This initiative will not only serve the current market needs for PSMA PET imaging but will also extend its reach to a broader patient population, particularly those who stand to benefit from a more advanced product. With enhancements in drug product manufacturing and copper-64 production, Clarity aims to provide 64Cu-SAR-bisPSMA promptly through centralized operations catering to extensive distribution needs across the U.S. and beyond.
Furthermore, Clarity's extensive network of existing supply agreements with industry partners like SpectronRx, Nusano, and Theragenics complements the new agreement with Nucleus RadioPharma by strengthening Clarity's production foothold. This multi-faceted approach ensures a reliable supply chain that can meet commercial demands while offering substantial network coverage across various geographic locations.
The partnership with Nucleus RadioPharma is a notable highlight, not merely due to their impressive manufacturing capabilities but also because of their recognized expertise in the healthcare system's operational aspects. Their commitment to driving advancements in radiopharmaceutical research and treatment stands as an invaluable asset to Clarity's mission of enhancing cancer treatment outcomes.
The Commercial Manufacturing Supply Agreement takes effect from April 14, 2026, and contains provisions for cancellation and extensions standard within industry practices. Although 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are not yet registered products, their anticipated approval is sparking excitement within the medical community, revealing promising prospects for the future of cancer diagnostics.
This forward collaboration not only reflects Clarity Pharmaceuticals' growth strategy but also strengthens the potential for groundbreaking advances in the treatment and diagnosis of prostate cancer, marking a significant stride in the realm of oncology.
Nucleus RadioPharma is recognized as an innovative contract development and manufacturing organization (CDMO) in the radiopharmaceutical field. Their state-of-the-art facility in Rochester, Minnesota, has the capacity to produce about 50,000 patient doses annually. Additionally, they are set to open a new facility in Spring House, Pennsylvania, in 2028, which is expected to increase production capacity to 600,000 doses of 64Cu-SAR-bisPSMA per year. This ambitious expansion will significantly bolster Clarity's ability to serve major commercial markets across the United States and select international locations in Europe.
This agreement builds on an existing partnership established with Nucleus RadioPharma, which includes a Master Services Agreement and a Clinical Supply Agreement for 67Cu-SAR-bisPSMA since November 2024. The signing of this latest agreement signifies a critical phase in Clarity's ongoing efforts to scale its manufacturing capabilities as it approaches the anticipated commercial launch of 64Cu-SAR-bisPSMA. This product's success will depend on the outcomes of Phase III registrational trials, namely AMPLIFY and CLARIFY, followed by approval from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA).
Dr. Geoffrey Johnson, Chief Scientific Officer at Nucleus RadioPharma, expressed enthusiasm over the production of 64Cu-SAR-bisPSMA, highlighting its potential in identifying small prostate cancer lesions that current standard imaging tests often overlook. Improved visualization could lead to earlier detection and subsequent better patient management, underlining the importance of effective diagnostic imaging in extending life and improving outcomes.
Stephen Hahn, CEO of Nucleus RadioPharma, also voiced his excitement about the partnership, emphasizing their shared goal with Clarity of enhancing treatment options for cancer patients. As the market launch of 64Cu-SAR-bisPSMA approaches, the recently released data providing insight into its efficacy compared to existing PSMA PET imaging adds to the anticipation surrounding this product.
Clarity’s Executive Chairperson, Dr. Alan Taylor, reiterated the significance of this manufacturing strategy, stating that establishing a robust supply system for 64Cu-SAR-bisPSMA will facilitate a large-scale commercial launch from day one. This initiative will not only serve the current market needs for PSMA PET imaging but will also extend its reach to a broader patient population, particularly those who stand to benefit from a more advanced product. With enhancements in drug product manufacturing and copper-64 production, Clarity aims to provide 64Cu-SAR-bisPSMA promptly through centralized operations catering to extensive distribution needs across the U.S. and beyond.
Furthermore, Clarity's extensive network of existing supply agreements with industry partners like SpectronRx, Nusano, and Theragenics complements the new agreement with Nucleus RadioPharma by strengthening Clarity's production foothold. This multi-faceted approach ensures a reliable supply chain that can meet commercial demands while offering substantial network coverage across various geographic locations.
The partnership with Nucleus RadioPharma is a notable highlight, not merely due to their impressive manufacturing capabilities but also because of their recognized expertise in the healthcare system's operational aspects. Their commitment to driving advancements in radiopharmaceutical research and treatment stands as an invaluable asset to Clarity's mission of enhancing cancer treatment outcomes.
The Commercial Manufacturing Supply Agreement takes effect from April 14, 2026, and contains provisions for cancellation and extensions standard within industry practices. Although 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are not yet registered products, their anticipated approval is sparking excitement within the medical community, revealing promising prospects for the future of cancer diagnostics.
This forward collaboration not only reflects Clarity Pharmaceuticals' growth strategy but also strengthens the potential for groundbreaking advances in the treatment and diagnosis of prostate cancer, marking a significant stride in the realm of oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.